Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jame Abraham MD, FACP

Jame Abraham MD, FACP

Chair of the Hematology/Medical Oncology Department, Director of Breast Oncology Program Taussig Cancer Institute and Professor of Medicine, Cleveland Clinic, Cleveland, Ohio

Recent Contributions to PracticeUpdate:

  1. Concurrent HER2-Directed Therapy and Stereotactic Radiosurgery for Breast Cancer Brain Metastases
  2. Capecitabine Plus Either Neratinib or Lapatinib for Patients With HER2+ Breast Cancer
  3. Neoadjuvant Chemotherapy for Invasive Lobular Breast Cancer
  4. Adjuvant T-DM1 for HER 2+ Breast Cancer: Critical Data From The KATHERINE Study
  5. New Data and Implications of HER2 Amplification by ctDNA
  6. Metastatic Breast Cancer: Later Lines of Therapy
  7. Metastatic Breast Cancer: Triple Negative
  8. Metastatic Breast Cancer: Hormone Receptor Positive
  9. Metastatic Breast Cancer: HER2 Positive
  10. Metastatic Breast Cancer: An Introduction

Most Read This Week

Recently Updated